CY2328B1 - 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity. - Google Patents

1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity.

Info

Publication number
CY2328B1
CY2328B1 CY0200043A CY0200043A CY2328B1 CY 2328 B1 CY2328 B1 CY 2328B1 CY 0200043 A CY0200043 A CY 0200043A CY 0200043 A CY0200043 A CY 0200043A CY 2328 B1 CY2328 B1 CY 2328B1
Authority
CY
Cyprus
Prior art keywords
pdeiv
phenylalkyl
imidazol
dihydro
derivatives
Prior art date
Application number
CY0200043A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcell Diels
Gil Jose Ignacio Andres
Gadea Francisco Javi Fernandez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2328B1 publication Critical patent/CY2328B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY0200043A 1995-04-06 2002-07-15 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity. CY2328B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26

Publications (1)

Publication Number Publication Date
CY2328B1 true CY2328B1 (en) 2004-02-06

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200043A CY2328B1 (en) 1995-04-06 2002-07-15 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity.

Country Status (26)

Country Link
US (2) US5994376A (cs)
EP (1) EP0819122B1 (cs)
JP (1) JP4562101B2 (cs)
KR (1) KR100406628B1 (cs)
CN (1) CN1068591C (cs)
AR (1) AR002732A1 (cs)
AT (1) ATE214052T1 (cs)
AU (1) AU702947B2 (cs)
CA (1) CA2216653C (cs)
CY (1) CY2328B1 (cs)
CZ (1) CZ293127B6 (cs)
DE (1) DE69619661T2 (cs)
DK (1) DK0819122T3 (cs)
ES (1) ES2174064T3 (cs)
HR (1) HRP960155A2 (cs)
HU (1) HU223324B1 (cs)
IL (1) IL117807A (cs)
MX (1) MX9707652A (cs)
MY (1) MY119254A (cs)
NO (1) NO314339B1 (cs)
NZ (1) NZ304877A (cs)
PL (1) PL187375B1 (cs)
PT (1) PT819122E (cs)
SI (1) SI0819122T1 (cs)
TW (1) TW332201B (cs)
WO (1) WO1996031485A1 (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
ATE236884T1 (de) * 1996-10-02 2003-04-15 Janssen Pharmaceutica Nv Pde-iv hemmende 2-cyanoiminoimidazol-derivate
BR9811499A (pt) 1997-07-10 2000-09-19 Janssen Pharmaceutica Nv "derivados da 6-azauracila como inibidores da il-5"
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
JP4778612B2 (ja) * 1998-04-01 2011-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｄｅｉｖ阻害ピリジン誘導体
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
CA2328250A1 (en) * 1998-04-14 1999-10-21 Smithkline Beecham Corporation Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
CA2352503C (en) 1998-11-23 2009-04-07 Janssen Pharmaceutica N.V. Il-5 inhibiting 6-azauracil derivatives
TR200101729T2 (tr) 1998-12-18 2001-10-22 Janssen Pharmaceutica N.V. IL-5 engelleyici 6-azaurasil türevleri
US6916810B2 (en) 2000-09-13 2005-07-12 Merck & Co., Inc. αν integrin receptor antagonists
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
JP4657297B2 (ja) * 2004-07-05 2011-03-23 ドン ファ ファーマシューティカル カンパニー リミテッド アレルギー性炎症疾患の予防及び治療用組成物
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
NZ601967A (en) * 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (cs) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
KR930703262A (ko) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 이미다졸리디논 화합물
DK0672031T3 (da) * 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
TW263495B (cs) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
CA2216653A1 (en) 1996-10-10
PL187375B1 (pl) 2004-06-30
HK1007880A1 (en) 1999-04-30
JP4562101B2 (ja) 2010-10-13
NZ304877A (en) 1999-06-29
SI0819122T1 (en) 2002-06-30
HRP960155A2 (en) 1997-10-31
PL322654A1 (en) 1998-02-16
CN1068591C (zh) 2001-07-18
PT819122E (pt) 2002-08-30
KR19980703449A (ko) 1998-11-05
ES2174064T3 (es) 2002-11-01
US20020068830A1 (en) 2002-06-06
EP0819122A1 (en) 1998-01-21
CA2216653C (en) 2009-05-26
HUP9801575A2 (hu) 1999-01-28
HU223324B1 (hu) 2004-06-28
US5994376A (en) 1999-11-30
AU5275596A (en) 1996-10-23
NO314339B1 (no) 2003-03-10
AR002732A1 (es) 1998-04-29
IL117807A (en) 2001-06-14
CZ314997A3 (cs) 1998-12-16
HUP9801575A3 (en) 1999-03-01
TW332201B (en) 1998-05-21
US6403805B1 (en) 2002-06-11
IL117807A0 (en) 1996-08-04
MX9707652A (es) 1997-11-29
NO974602L (no) 1997-10-06
CN1181072A (zh) 1998-05-06
ATE214052T1 (de) 2002-03-15
DE69619661D1 (de) 2002-04-11
KR100406628B1 (ko) 2004-05-31
EP0819122B1 (en) 2002-03-06
DK0819122T3 (da) 2002-07-01
NO974602D0 (no) 1997-10-06
AU702947B2 (en) 1999-03-11
MY119254A (en) 2005-04-30
WO1996031485A1 (en) 1996-10-10
JPH11503136A (ja) 1999-03-23
DE69619661T2 (de) 2002-10-31
CZ293127B6 (cs) 2004-02-18

Similar Documents

Publication Publication Date Title
SI0819122T1 (en) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity
ZA987037B (en) Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity.
ZA962522B (en) Quinazoline derivatives.
AU7908098A (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
ZA985352B (en) Barbituric acid derivatives with antimetastatic and antitumor activity.
ZA965418B (en) Quick-fermented feed, its preparation and uses.
AU703235B2 (en) 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives having PDE IV and cytokine inhibiting activity
GR3036656T3 (en) 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity
ZA938591B (en) Insecticidal 5-substituted-2,4-diaminopyrimidine derivatives
ZA963620B (en) (Het)aryloxy-, -thio- and -aminocrotonates, their preparation and their use.
HUP9900374A3 (en) Diarylalkenylamine derivatives and pharmaceutical compns. contg. them
PL327686A1 (en) Derivatives of @-amino 5,6-dichlorobenzimidazole exhibiting antiviral activity
ATE305455T1 (de) 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität
ZA989571B (en) 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
ZA967997B (en) Urea derivatives.
ZA986160B (en) 2,4,4-trisubstituted-1,3-dioxolone antifungals.
ZA93733B (en) New amidine derivatives, the preparation and use thereof.
ZA962754B (en) 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives.
HK1024700A (en) 9,10-diazatricyclo 4.2.1.1 2,5] decane and 9,10-diazatricyclo 3.3.1.1 2,6] decane derivatives having analgesic activity
HUP9903260A3 (en) 2,4-diaminopyrimidine derivatives with antibiotic activity, preparation and use thereof
ZA974484B (en) Antimicrobial activity.
ZA9711039B (en) Benzothiophenecarboxamide derivatives and PGD2-antagonists comprising them.
ZA926812B (en) O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
ZA975496B (en) 1, 2, 4-benzothiadiazine derivatives, their preparation and use.
ZA929394B (en) Piperidine derivatives, their preparation and use.